Ehlers-Danlos · Connective tissue
Generalized Hypermobility Spectrum Disorder · G-HSD
Symptomatic generalized hypermobility that does not meet hEDS criterion 2. Real diagnosis, similar management.
Description
Generalized hypermobility spectrum disorder, G-HSD, is a clinical diagnosis for symptomatic generalized joint hypermobility that does not meet the full 2017 criteria for hypermobile Ehlers-Danlos syndrome, hEDS. The category was introduced alongside the revised hEDS criteria by the International Consortium on the Ehlers-Danlos Syndromes (Castori et al., American Journal of Medical Genetics Part C, 2017; Malfait et al., American Journal of Medical Genetics Part C, 2017) to give a clinical home to a population that prior frameworks had described as joint hypermobility syndrome or EDS hypermobility type.
A G-HSD diagnosis requires generalized joint hypermobility, established by a Beighton score at the age-appropriate cutoff or by the supplementary five-point questionnaire when historical hypermobility is the relevant evidence, plus musculoskeletal symptoms such as chronic joint pain, recurrent dislocations or subluxations, or soft tissue injury. The criteria for hEDS, which include systemic connective tissue features and a strict family history component in criterion 2, are not all met. G-HSD has no established gene and no specific molecular test. Diagnosis is clinical and requires exclusion of other heritable connective tissue disorders, including the 13 EDS subtypes with known molecular causes.
The 2017 framework names three additional pattern-based hypermobility spectrum categories: peripheral HSD, P-HSD, with hypermobility limited to hands and feet; localized HSD, L-HSD, with one joint or one body region; and historical HSD, H-HSD, with current low Beighton scores but documented past hypermobility. G-HSD and hEDS sit at the same point on the symptom-severity axis in the 2017 model, separated by the systemic and family-history components of the hEDS criteria rather than by symptom burden.
Subsequent literature has tested that intent. Aubry-Rozier et al. (Joint Bone Spine, 2021) and several mixed-clinic cohorts in the years following the 2017 publication reported that adults carrying G-HSD diagnoses presented with pain levels, fatigue burden, and functional limitation comparable to adults with hEDS at the same clinic. The current consensus position from EDS subtype working groups is that G-HSD and hEDS warrant equivalent clinical attention, with diagnostic distinction useful for research stratification rather than triage.
Treatments to date
No drug therapy is approved for G-HSD, and no disease-specific drug is in late-stage development. Care is multidisciplinary and symptom-targeted, and the published treatment approach is identical to the approach used in hEDS.
Physical therapy with a clinician familiar with hypermobility is the cornerstone. Programs emphasize joint stabilization through targeted strengthening, proprioceptive training, and graded loading rather than the unloaded stretching that worsens symptoms in many hypermobile adults. Pain management combines pharmacologic and non-pharmacologic approaches, with attention to the limited evidence base for chronic pain in hypermobile populations and the documented variability of local anesthetic response. Occupational therapy addresses joint protection during daily tasks and at work.
Comorbid conditions are part of routine assessment. The dysautonomia spectrum, including postural orthostatic tachycardia syndrome, gastrointestinal motility disorders, and mast cell activation features are evaluated and managed on their own pathways when present. Mental health support is integrated, given the documented burden of chronic pain and diagnostic delay in this population.
Genetic counseling addresses the absence of a confirmed monogenic cause for G-HSD and the implications for family members. When clinical features suggest a defined EDS subtype or another heritable connective tissue disorder, targeted gene panel testing is the next step. Research directions named by recent reviews include genetic studies of large G-HSD and hEDS cohorts, validated outcome measures for hypermobility-related symptom burden, and clinical trials designed to enroll across the G-HSD and hEDS populations rather than separating them.